From Washington, D.C., at the Interscience Conference on Antimicrobial Agents and Chemotherapy
In a preliminary study, a vaccine against a virus that can cause cancer has proved 94 percent effective in women. The success sets the stage for an enhanced version of the vaccine and the massive trial needed for government approval of the final product, which is intended to protect against the human papillomavirus (HPV).
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.